Biosensor market potential is in "niche" segments, NIST researcher says.
This article was originally published in The Gray Sheet
Executive Summary
BIOSENSOR MARKET POTENTIAL LIES IN "NICHE" AREAS, such as home monitoring for glucose and cholesterol, Howard Weetall, National Institute of Standards and Technology, Gaithersburg, Maryland, said at a symposium during the recent American Association for Clinical Chemistry annual meeting. Biosensor technology "still has uncertainty," he said. "It has sensitivity problems, generally it's more expensive, and therefore it's not going to be able to...move into some of the major clinical markets" such as thyroid testing, reproductive testing, or standard clinical chemistry.